Contact Us
Contact Us

News & Events

Featured News

Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Recent News

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer

EBC-129: Phase 1 study of our first-in-class, anti N-glycosylated CEACAM5 & 6 ADC in solid tumours

Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer

EBC-129: Phase 1 study of our first-in-class, anti N-glycosylated CEACAM5 & 6 ADC in solid tumours

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

First Made-in-Singapore Antibody-Drug Conjugate EBC-129 progresses to Phase 1B Dose Expansion

ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics

XtalPi and EDDC sign MoU, minting new collaboration to empower biomedical innovation with robotics and Large Language Models (LLM)

EARO Review (2020 – 2022) – A Review of EARO’s first 3 years

Helpful Links

Contact Us

© Experimental Drug Development Centre All Rights Reserved